Literature DB >> 16118082

Accelerated radiotherapy for advanced laryngeal cancer.

Hedda Haugen1, Karl-Axel Johansson, Hasse Ejnell, Staffan Edström, Claes Mercke.   

Abstract

The purpose of this study was to evaluate a single institution's outcome for patients with advanced laryngeal cancer treated with accelerated radiotherapy (RT). Fifty-eight patients with advanced laryngeal cancer (T3/T4N0/N + M0) were treated with curative intent with accelerated RT during the period 1990-1998. Patients received radiotherapy alone or with induction chemotherapy. The 5-year local control (LC) and loco-regional control (LRC) probabilities were both 49% for T3 and 75% for T4 tumors. The 5-year disease-free survival probability was 46% and 68% and overall survival probability was 30% and 39% for T3 and T4 tumors respectively. No significant statistical difference in outcome was found, either between T3 and T4 tumors, or between patients who received induction chemotherapy and those who did not. The treatment results for advanced laryngeal cancer at this institution were comparable to those reported in the literature. The results for T3 and T4 were similar. T4 classification alone should not be an exclusion criterion for larynx preservation. Overall survival was poor, partly because of a high incidence of deaths from intercurrent diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118082     DOI: 10.1080/02841860510029950

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  2 in total

1.  Survival outcome depending on different treatment strategies in advanced stages III and IV laryngeal cancers: an audit of data from two European centres.

Authors:  Therese R Karlsson; Mohammed Al-Azzawe; Luaay Aziz; David Hurman; Caterina Finizia
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-08-31       Impact factor: 2.503

2.  Organ preservation in T4a laryngeal cancer: is transoral laser microsurgery an option?

Authors:  Martin Canis; Friedrich Ihler; Alexios Martin; Hendrik A Wolff; Christoph Matthias; Wolfgang Steiner
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-14       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.